minaprine has been researched along with Amyotrophic Lateral Sclerosis in 1 studies
minaprine: Agr 1240 refers to di-HCl; short-acting type A MAO inhibitor (MAOI) of mild potency; structure
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, T | 1 |
| Benmohamed, R | 1 |
| Kim, J | 1 |
| Smith, K | 1 |
| Amante, D | 1 |
| Morimoto, RI | 1 |
| Kirsch, DR | 1 |
| Ferrante, RJ | 1 |
| Silverman, RB | 1 |
1 other study available for minaprine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Blood-Brain Barrier; Caco-2 Cells; Cell Membrane Permeabilit | 2012 |